Skip to main content

Lupus Erythematosus News

Related terms: Discoid Lupus Erythematosus, DLE

FDA Approves Belimumab Autoinjector for Pediatric Systemic Lupus Erythematosus

WEDNESDAY, May 22, 2024 – The U.S. Food and Drug Administration has approved a 200-mg subcutaneous route of administration of Benlysta (belimumab) for patients 5 years of age and older with active...

FDA Approves Benlysta (belimumab) Autoinjector for Children with Systemic Lupus Erythematosus

Philadelphia, PA May 20 2024 – GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg subcutaneous route of administration of Benlysta...

CAR T-Cell Therapy Feasible, Safe for Autoimmune Diseases

WEDNESDAY, Feb. 21, 2024 – CD19 chimeric antigen receptor (CAR) T-cell therapy seems feasible, safe, and efficacious for patients with different autoimmune diseases, according to a study published...

GSK Receives US Approval of Benlysta for Intravenous Use in Children with Lupus Aged Five Years and Above

London UK, Philadelphia USA April 26, 2019 – GSK today announced that the US Food and Drug Administration (FDA) has approved, under priority review, the use of the intravenous (IV) formulation of...

GSK Receives FDA Approval for a New Self-Injectable Formulation of Benlysta (belimumab) for Systemic Lupus Erythematosus

London, UK 21 July 2017 – GSK announced today that the US Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Benlysta (belimumab) for the treatment of adult patients...

FDA Approves Benlysta to Treat Lupus

March 9, 2011 – The U.S. Food and Drug Administration today approved Benlysta (belimumab) to treat patients with active, autoantibody-positive lupus (systemic lupus erythematosus) who are receiving...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Systemic Lupus Erythematosus, Autoimmune Disorders

Related drug support groups

Benlysta